Form 4: Equillium Grants 1.15M Stock Options to President & CSO

Equillium, Inc. granted 1,150,000 employee stock options to Stephen Connelly, President and CSO, with an exercise price of $1.31.

Summary

• Stephen Connelly, President and CSO, and a Director of Equillium, Inc. (EQ), was granted 1,150,000 employee stock options.
• The transaction date for this grant was January 7, 2026.
• The exercise price for these options is $1.31 per share.
• The options have an expiration date of January 6, 2036.
• The vesting schedule for the options is 25% on the first anniversary of the vesting commencement date, with the remaining 75% vesting in 36 equal monthly installments over the subsequent three years.

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is generally a neutral to slightly positive event, as it aligns management incentives with long-term shareholder value. It is a standard compensation practice and does not directly reflect operational performance or financial results.

Positives

• The grant of stock options aligns the interests of President and CSO Stephen Connelly with those of shareholders, incentivizing long-term company performance.
• The options have a 10-year expiration date, providing a substantial window for value creation.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the vesting schedule of the granted options, which implies a long-term incentive structure for the executive.

Industry Context

The grant of employee stock options is a common practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key executives. This compensation structure is designed to align management's long-term performance with shareholder value creation, particularly in companies with significant research and development cycles like Equillium.

Comparison to Industry Standards

• The use of employee stock options as a form of executive compensation is a standard practice across the biotechnology and pharmaceutical sectors, comparable to compensation strategies at companies like Amgen, Gilead Sciences, or Biogen.
• The vesting schedule, with an initial cliff vesting followed by monthly installments over three years, is a typical structure designed to encourage long-term commitment and performance, consistent with industry benchmarks for executive incentive plans.

Stakeholder Impact

• Shareholders: The grant aims to align the interests of a key executive with shareholders, potentially leading to enhanced long-term value creation.
• Employees: This transaction is specific to a senior executive and does not directly impact the broader employee base, though it reflects the company's executive compensation strategy.

Next Steps

• The options will begin vesting according to the specified schedule: 25% on the first anniversary of the vesting commencement date, and the remainder in 36 equal monthly installments thereafter for the following three years.

Key Dates

Keywords

Equillium, EQ, stock option, executive compensation, Form 4, insider transaction, vesting, biotechnology